Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmin is a serine protease enzyme primarily responsible for breaking down fibrin blood clots in a process known as fibrinolysis. It is generated from its inactive zymogen form, plasminogen, which circulates throughout the body and is activated by tissue-type or urokinase-type plasminogen activators. Beyond clot dissolution, plasmin can also degrade various extracellular matrix proteins and activate other proteins by limited proteolysis, playing roles in tissue remodeling and cell migration. Its activity is tightly regulated by inhibitors such as α2-antiplasmin. Dysregulation or excessive activity contributes to hemorrhagic conditions, chronic inflammation, and tissue damage.
Serine protease inhibition (indirectly, via plasminogen activators or directly by inhibitors)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine protease (plasmin) (None).